Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Dimmitt

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Clinical Pharmacology|April 18, 2001
Effect of alosetron on the pharmacokinetics of fluoxetineD L D'Souza, D C Dimmitt, D K Robbins, et al.
American Journal of Therapeutics|July 29, 1999
Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapyC L Lippert, D C Dimmitt, L Martin, et al.
Biopharmaceutics & Drug Disposition|March 23, 1999
Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1D C Dimmitt, Y S Choo, L A Martin, et al.
Biopharmaceutics & Drug Disposition|March 23, 1999
Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2D C Dimmitt, Y S Choo, L A Martin, et al.
Journal of Clinical Pharmacology|September 30, 1998
Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairmentD C Dimmitt, A K Shah, T Arumugham, et al.
The Annals of Pharmacotherapy|February 26, 1998
Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylateD C Dimmitt, T L Hunt, A J Spalitto, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Clinical Pharmacology|April 18, 2001
Effect of alosetron on the pharmacokinetics of fluoxetineD L D'Souza, D C Dimmitt, D K Robbins, et al.
American Journal of Therapeutics|July 29, 1999
Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapyC L Lippert, D C Dimmitt, L Martin, et al.
Biopharmaceutics & Drug Disposition|March 23, 1999
Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1D C Dimmitt, Y S Choo, L A Martin, et al.
Biopharmaceutics & Drug Disposition|March 23, 1999
Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2D C Dimmitt, Y S Choo, L A Martin, et al.
Journal of Clinical Pharmacology|September 30, 1998
Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairmentD C Dimmitt, A K Shah, T Arumugham, et al.
The Annals of Pharmacotherapy|February 26, 1998
Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylateD C Dimmitt, T L Hunt, A J Spalitto, et al.
Pageof 2